Abstract
Background and Objective: The analgesic effect of codeine depends on the formation of the opioid metabolites morphine and morphine-6-glucuronide. Different factors have been shown or suspected to affect the safety and efficacy of codeine treatment. The objective of the current study is to assess and quantify the impact of important pharmacokinetic factors, using a mechanistic modeling approach.
Methods: By means of a generic modeling approach integrating prior physiologic knowledge, we systematically investigated the complex dependence of opioid exposure on cytochrome P450 2D6 and 3A4 (CYP2D6 and CYP3A4), and uridine diphosphate glucuronosyltransferase 2B7 (UGT2B7) activity, as well as renal function, by means of a virtual clinical trial.
Results: First, the known dominant role of CYP2D6 activity for morphine exposure was reproduced. Second, the model demonstrated that mild and moderate renal impairment and co-administration of CYP3A4 inhibitors have only minor influences on opioid exposure. Third, the model showed — in contrast to current opinion — that increased UGT2B7 activity is associated with a decrease in active opioid exposure.
Conclusion: Overall, the model-based analysis predicts a wide range of morphine levels after codeine administration and supports recent doubts about safe and efficacious use of codeine for analgesia in non-genotyped individuals.
Similar content being viewed by others
References
Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007 Jan; 53(1): 33–5
Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006 Aug 19; 368(9536): 704
Magnani B, Evans R. Codeine intoxication in the neonate. Pediatrics 1999 Dec; 104(6): e75
Ferreiros N, Dresen S, Hermanns-Clausen M, et al. Fatal and severe codeine intoxication in 3-year-old twins: interpretation of drug and metabolite concentrations. Int J Legal Med 2009 Sep; 123(5): 387–94
Hermanns-Clausen M, Weinmann W, Auwarter V, et al. Drug dosing error with drops: severe clinical course of codeine intoxication in twins. Eur J Pediatr 2009 Jul; 168(7): 819–24
Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 2009 Aug 20; 361(8): 827–8
Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant — an ultra-rapid metabolizer. Paediatr Anaesth 2007 Jul; 17(7): 684–7
Lee AC, Chan R, So KT. A case of probable codeine poisoning in a young infant after the use of a proprietary cough and cold medicine. Hong Kong Med J 2004 Aug; 10(4): 285–7
Frei MY, Nielsen S, Dobbin MD, et al. Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. Med J Aust 2010 Sep 6; 193(5): 294–6
Dalen P, Frengell C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997 Oct; 19(5): 543–4
Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004 Dec 30; 351(27): 2827–31
Lötsch J, Rohrbacher M, Schmidt H, et al. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 2009 Jul; 144(1–2): 119–24
Desmeules J, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41(1): 23–6
Persson K, Sjöström S, Sigurdardottir I, et al. Patient-controlled analgesia (PC A) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br J Clin Pharmacol 1995; 39(2): 182–6
Sindrup SH, Poulsen L, Brøsen K, et al. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993; 53(3): 335–9
Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5(6): 335–46
Eissing T, Kuepfer L, Becker C, et al. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol 2011; 2: 4
Willmann S, Edginton AN, Coboeken K, et al. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 2009 Dec; 86(6): 634–43
Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001 Oct; 11(7): 573–85
Court MH, Krishnaswamy S, Hao Q, et al. Evaluation of 3−azido-3′-deoxy-thymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003 Sep; 31(9): 1125–33
Raungrut P, Uchaipichat V, Elliot DJ, et al. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole and methadone in humans. J Pharmacol Exp Ther 2010 May 18; 334(2): 609–18
Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007 Aug; 7(4): 257–65
Yue QY, Alm C, Svensson JO, et al. Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther Drug Monit 1997 Oct; 19(5): 539–42
Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996 Sep; 278(3): 1165–74
Kenworthy KE, Bloomer JC, Clarke SE, et al. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999 Nov; 48(5): 716–27
Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007 Jun; 34(3): 401–31
Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values. Annals of the ICRP 2002; 32(3): 1–277
Paris P, Yealy D. Pain management. In: Marx JA, editor. Rosen’s emergency medicine: concepts and clinical practice. St Louis (MO): Mosby, 2002: 2555–77
Zimmer G. Acute pain management. In: Tintinalli J, Kelen G, Stapczynski J, editors. Emergency medicine: a comprehensive study guide. New York: McGraw-Hill, 2004: 257–64
Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992 Aug; 34(2): 130–8
Smith TW, Binning AR, Dahan A. Efficacy and safety of morphine-6-glucuronide (M6G) for postoperative pain relief: a randomized, double-blind study. Eur J Pain 2009 Mar; 13(3): 293–9
Vossen M, Sevestre M, Niederalt C, et al. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 2007; 4: 13
Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine’s respiratory, psychomotor and miotic effects. J Pharmacol Exp Ther 1997 Apr; 281(1): 330–6
Vevelstad M, Pettersen S, Tallaksen C, et al. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. Eur J Clin Pharmacol 2009 Aug; 65(8): 795–801
Aitkenhead AR, Vater M, Achola K, et al. Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth 1984 Aug; 56(8): 813–9
Sawe J, Svensson JO, Odar-Cederlof I. Kinetics of morphine in patients with renal failure. Lancet 1985 Jul 27; 2(8448): 211
Woolner DF, Winter D, Frendin TJ, et al. Renal failure does not impair the metabolism of morphine. Br J Clin Pharmacol 1986 Jul; 22(1): 55–9
Hanna MH, D’Costa F, Peat SJ, et al. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 1993 May; 70(5): 511–4
Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 2010 Feb; 42(1): 209–24
Kwara A, Lartey M, Boamah I, et al. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol 2009 Sep; 49(9): 1079–90
Holthe M, Rakvag TN, Klepstad P, et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003; 3(1): 17–26
Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a casecontrol study. Clin Pharmacol Ther 2009 Jan; 85(1): 31–5
Sawyer MB, Innocenti F, Das S, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003 Jun; 73(6): 566–74
Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos 2008 Apr; 36(4): 688–94
Nagano E, Yamada H, Oguri K. Characteristic glucuronidation pattern of physiologic concentration of morphine in rat brain. Life Sci 2000 Oct 6; 67(20): 2453–64
Madadi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics 2008 Sep; 9(9): 1267–84
Quiding H, Anderson P, Bondesson U, et al. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol 1986; 30(6): 673–7
Lötsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004; 43(14): 983–1013
Poulsen L, Brøsen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51(3–4): 289–95
Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007 Feb; 17(2): 93–101
Acknowledgments
The authors acknowledge financial support by the Virtual Liver Initiative (www.virtual-liver.de <http://www.virtual-liver.de>), QuantPro Initiative (www.ptj.de/quantpro <http://www.ptj.de/quantpro>), FORSYS-Partner Initiative (www.forsys.net <http://www.forsys.net>), and Services@MediGrid Initiative (www.medigrid.de <http://www.medigrid.de>), partly funded by the German Federal Ministry of Research and Education (BmBF).
T.E., J.L., and S.W. are employees of Bayer Technology Services GmbH, the company that owns and commercializes the software platform used for the simulations described in the manuscript (PK-Sim® and MoBi®), as well as parent company stock owners.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eissing, T., Lippert, J. & Willmann, S. Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide. Mol Diagn Ther 16, 43–53 (2012). https://doi.org/10.1007/BF03256429
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256429